leisure time -WSS

leisure time

author：focus 2025-09-28 02:27:40 - browse：9

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Research misconduct: Proposed new rules face resistance

Wikipedia

WSS

When waiting feels immoral: Empathy in the emergency department

AI generated plenty of interest at JPM but not a lot of trust

Alnylam reports growth in sales of rare disease treatments

The a glaring gap in research on serious mental illness and primary care

My yearlong odyssey to get my son’s ADHD medication covered

H.R. 3 is the wrong path to lower drug costs

focus

leisure time

focus

Virginia high school admissions case could be legal follow

eGenesis tests gene

The high cost of giving birth even with insurance

Personalized medicine goes far beyond genetics

Apple is now the first public company to be valued at $3 trillion

FDA approves Sage Therapeutics’ rapid

Bright Health sells Medicare Advantage business to Molina

Parkinson’s finding may lead to tests and, someday, treatments

Novavax promises a turnaround & Lilly roils the obesity market

Independent physicians launch a new lobbying group

leisure time

It costs an awful lot of money to give away a kidney

NIH director takes cautious approach to Biden drug pricing priority

Prior authorization will have to move faster under new Biden rule

Research misconduct: Proposed new rules face resistance

The a glaring gap in research on serious mental illness and primary care

How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

Wikipedia

entertainment

Wikipedia